NYMX   $0.2001  -19.24% Market Open

Nymox Pharmaceutical Corp
Last Events:

2023-07-18 Trend pattern changed from расходящийся треугольник to нисходящий треугольник.

2023-07-18 Signal in Stochastic changed from bullish to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: exit from the oversold zone.

2023-07-18 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: entry into the oversold zone.

2023-07-18 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-07-18 Signal in EMA100 changed from bullish reversal to bearish reversal. 2023-06-07 the price crossed down the moving average line and trying to form a short-term downside trend.

2023-07-18 Signal in EMA50 changed from bullish reversal to bearish reversal. 2023-06-05 the price crossed down the moving average line and demonstrates a downside trend.

2023-07-18 Trend Power changed from almost flat to slow.

2023-07-18 Trend changed from turning up to turning down.


Current temperature: 3.01
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd - Sell -
stoch Sell - -
ma20 ActivelyBuy Sell -
ma50 Sell - -
ma100 Sell Sell -
Candlestick PatternJuly 3, 2023 Bullish Engulfing - is characterized by a large white body engulfing a preceding smaller black body, which appears during a downtrend. Considered to be a bullish reversal pattern.
ISIN BSP733981026
ceo Dr. Paul Averback DABP, M.D.
Website https://nymox.com
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.